Compared with normal donators, the expression of CCL24 and number of cardiac M2 macrophages in heart were higher in heart failure patients, the same as plasma CCL24. Treatment with CCL24 antibody hindered Ang II (1500 ng/kg/min)–induced cardiac adverse remodeling through preventing cardiac hypertrophy and fibrosis. This evidence concerns the gene AGT and cardiac hypertrophy.